translation agency

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update
Gilead Sciences Begins Human Clinical Trials of Topical GS 504

March 21, 1994
Business Wire (03/15/94)

Gilead Sciences Inc. has begun human clinical testing of its drug candidate GS 504, for the treatment of genital warts caused by the human papillomavirus (HPV) in HIV patients. The study will evaluate the safety and potential efficacy of topical GS 504 when applied once daily to genital warts. The first patient in the dose-escalation study is being enrolled at the University of Washington; however, the trial will also be conducted through the Conant Medical Research Group in San Francisco and the Houston Clinical Research Network. Recent studies suggest that progression of genital warts, the most common form of sexually transmitted disease, may be accelerated in patients infected with HIV.